Agios Pharmaceuticals Inc (AGIO) : Alpinvest Partners B.v. added new position in Agios Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 30,000 shares of Agios Pharmaceuticals Inc which is valued at $1,212,600 , the company said in a statement filed on Aug 10, 2016 with the SEC.Agios Pharmaceuticals Inc makes up approximately 2.03% of Alpinvest Partners B.v.’s portfolio.
Other Hedge Funds, Including , Blackrock Advisors boosted its stake in AGIO in the latest quarter, The investment management firm added 240,636 additional shares and now holds a total of 253,023 shares of Agios Pharmaceuticals Inc which is valued at $10,227,190. Agios Pharmaceuticals Inc makes up approx 0.01% of Blackrock Advisors’s portfolio. Quantbot Technologies Lp added AGIO to its portfolio by purchasing 8,997 company shares during the most recent quarter which is valued at $414,042. Agios Pharmaceuticals Inc makes up approx 0.04% of Quantbot Technologies Lp’s portfolio.Financial Architects Inc reduced its stake in AGIO by selling 400 shares or 28.29% in the most recent quarter. The Hedge Fund company now holds 1,014 shares of AGIO which is valued at $46,198. Agios Pharmaceuticals Inc makes up approx 0.01% of Financial Architects Inc’s portfolio.Checchi Capital Advisers boosted its stake in AGIO in the latest quarter, The investment management firm added 40 additional shares and now holds a total of 98 shares of Agios Pharmaceuticals Inc which is valued at $4,139.Creative Planning reduced its stake in AGIO by selling 900 shares or 9.91% in the most recent quarter. The Hedge Fund company now holds 8,179 shares of AGIO which is valued at $334,603.
Agios Pharmaceuticals Inc closed down -0.65 points or -1.60% at $39.9 with 3,75,776 shares getting traded on Friday. Post opening the session at $40.23, the shares hit an intraday low of $39.32 and an intraday high of $40.89 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Agios Pharmaceuticals Inc reported $-1.47 EPS for the quarter, missing the analyst consensus estimate by $ -0.17 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-1.30. The company had revenue of $6.97 million for the quarter, compared to analysts expectations of $41.37 million. The company’s revenue was down -47.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.85 EPS.
Many Wall Street Analysts have commented on Agios Pharmaceuticals Inc. Agios Pharmaceuticals Inc was Upgraded by JP Morgan to ” Overweight” on Jun 13, 2016. Company shares were Reiterated by SunTrust on May 18, 2016 to “Buy”, Firm has raised the Price Target to $ 65 from a previous price target of $57 .Company shares were Reiterated by Sun Trust Rbsn Humphrey on May 18, 2016 to “Buy”, Firm has raised the Price Target to $ 65 from a previous price target of $57 .
Agios Pharmaceuticals Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221 AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available selective potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.